MX2019001722A - Compuestos de captura de aldehido y usos de los mismos. - Google Patents
Compuestos de captura de aldehido y usos de los mismos.Info
- Publication number
- MX2019001722A MX2019001722A MX2019001722A MX2019001722A MX2019001722A MX 2019001722 A MX2019001722 A MX 2019001722A MX 2019001722 A MX2019001722 A MX 2019001722A MX 2019001722 A MX2019001722 A MX 2019001722A MX 2019001722 A MX2019001722 A MX 2019001722A
- Authority
- MX
- Mexico
- Prior art keywords
- trapping compounds
- aldehyde trapping
- aldehyde
- hne
- mda
- Prior art date
Links
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000000266 injurious effect Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378065P | 2016-08-22 | 2016-08-22 | |
| PCT/US2017/047945 WO2018039192A1 (en) | 2016-08-22 | 2017-08-22 | Aldehyde trapping compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019001722A true MX2019001722A (es) | 2019-07-04 |
Family
ID=61190657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001722A MX2019001722A (es) | 2016-08-22 | 2017-08-22 | Compuestos de captura de aldehido y usos de los mismos. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20180050989A1 (enExample) |
| EP (1) | EP3500256A4 (enExample) |
| JP (1) | JP2019532029A (enExample) |
| CN (1) | CN109640983A (enExample) |
| AU (1) | AU2017317524A1 (enExample) |
| CA (1) | CA3032521A1 (enExample) |
| CO (1) | CO2019001625A2 (enExample) |
| MX (1) | MX2019001722A (enExample) |
| WO (1) | WO2018039192A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006249866B2 (en) | 2005-05-26 | 2011-10-13 | Aldeyra Therapeutics, Inc. | Compositions and methods of treating retinal disease |
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| CN111135171B (zh) | 2013-01-23 | 2023-09-08 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| CN118724806A (zh) | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| KR20180116416A (ko) | 2016-02-28 | 2018-10-24 | 알데이라 테라퓨틱스, 아이엔씨. | 사이클로덱스트린으로의 알레르기성 안질환의 치료 |
| CN109152774A (zh) | 2016-05-09 | 2019-01-04 | 奥尔德拉医疗公司 | 眼部炎性病症和疾病的组合治疗 |
| WO2018170476A1 (en) | 2017-03-16 | 2018-09-20 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| CN111356451A (zh) * | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | 炎性病症的治疗 |
| US20200038392A1 (en) | 2018-08-03 | 2020-02-06 | Aldeyra Therapeutics, Inc. | Topical compositions and methods of preparation and use |
| CN112714762A (zh) | 2018-08-06 | 2021-04-27 | 奥尔德拉医疗公司 | 多晶型化合物及其用途 |
| CN113056353B (zh) | 2018-09-25 | 2022-11-01 | 奥尔德拉医疗公司 | 用于治疗干眼病的调配物 |
| WO2020123730A1 (en) * | 2018-12-12 | 2020-06-18 | Teva Pharmaceuticals International Gmbh | Solid state forms of reproxalap |
| US11786518B2 (en) | 2019-03-26 | 2023-10-17 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations and uses thereof |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| CN113784954A (zh) * | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| JP2023507900A (ja) * | 2019-12-30 | 2023-02-28 | 中国医▲薬▼研究▲開▼▲発▼中心有限公司 | 三環式化合物、及びその調製方法、及びその医薬的使用 |
| CA3174416A1 (en) * | 2020-04-13 | 2021-10-21 | Todd Brady | Quinoline compounds for treating lung, liver, and kidney diseases, disorders, or conditions |
| WO2021231792A1 (en) * | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| WO2021248031A1 (en) * | 2020-06-04 | 2021-12-09 | Aldeyra Therapeutics, Inc. | Dry eye disease biomarkers and their use for treatment |
| JP2024503325A (ja) * | 2020-12-29 | 2024-01-25 | 中国医▲薬▼研究▲開▼▲発▼中心有限公司 | 三環式化合物、及びその調製方法、及びその医薬的使用 |
| WO2022267930A1 (zh) * | 2021-06-25 | 2022-12-29 | 中国医药研究开发中心有限公司 | 三环化合物及其制备方法和医药用途 |
| WO2023192372A1 (en) * | 2022-03-29 | 2023-10-05 | Aldeyra Therapeutics, Inc. | Methods of treating sjögren-larssen syndrome |
| CN122458974A (zh) * | 2023-12-28 | 2026-07-24 | 珠海联邦制药股份有限公司 | Rasp抑制剂在制备治疗或预防慢性咳嗽、哮喘及酒精性肝病疾病的药物中的应用 |
| CN120607478A (zh) * | 2024-03-06 | 2025-09-09 | 深圳湾实验室 | 预防和治疗醛代谢紊乱引起的相关疾病的化合物及其用途 |
| CN121652111A (zh) * | 2024-09-11 | 2026-03-13 | 深圳新锐基因科技有限公司 | 一种基于ai设计的活性醛类物质抑制剂及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006249866B2 (en) * | 2005-05-26 | 2011-10-13 | Aldeyra Therapeutics, Inc. | Compositions and methods of treating retinal disease |
| KR20150118106A (ko) * | 2012-12-20 | 2015-10-21 | 알데이라 테라퓨틱스, 아이엔씨. | 페리-카르비놀 |
| CN111135171B (zh) * | 2013-01-23 | 2023-09-08 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| KR101646666B1 (ko) * | 2015-03-26 | 2016-08-08 | 엘지이노텍 주식회사 | 발광 소자, 이 소자를 포함하는 발광 소자 패키지, 및 이 패키지를 포함하는 조명 장치 |
| KR20180073553A (ko) * | 2015-08-21 | 2018-07-02 | 알데이라 테라퓨틱스, 아이엔씨. | 알데히드 접합체 및 이의 용도 |
| CN118724806A (zh) * | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
-
2017
- 2017-08-22 EP EP17844261.2A patent/EP3500256A4/en not_active Withdrawn
- 2017-08-22 MX MX2019001722A patent/MX2019001722A/es unknown
- 2017-08-22 CN CN201780051309.5A patent/CN109640983A/zh active Pending
- 2017-08-22 WO PCT/US2017/047945 patent/WO2018039192A1/en not_active Ceased
- 2017-08-22 CA CA3032521A patent/CA3032521A1/en not_active Abandoned
- 2017-08-22 AU AU2017317524A patent/AU2017317524A1/en not_active Abandoned
- 2017-08-22 JP JP2019510396A patent/JP2019532029A/ja active Pending
- 2017-08-22 US US15/682,955 patent/US20180050989A1/en not_active Abandoned
-
2019
- 2019-02-22 CO CONC2019/0001625A patent/CO2019001625A2/es unknown
- 2019-04-04 US US16/374,845 patent/US20200062712A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180050989A1 (en) | 2018-02-22 |
| CA3032521A1 (en) | 2018-03-01 |
| CN109640983A (zh) | 2019-04-16 |
| CO2019001625A2 (es) | 2019-04-30 |
| WO2018039192A1 (en) | 2018-03-01 |
| JP2019532029A (ja) | 2019-11-07 |
| US20200062712A1 (en) | 2020-02-27 |
| AU2017317524A1 (en) | 2019-02-21 |
| EP3500256A1 (en) | 2019-06-26 |
| EP3500256A4 (en) | 2020-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018002157A (es) | Conjugados de aldehido y usos de los mismos. | |
| MX2019012878A (es) | Terapias para el tratamiento de enfermedades asociadas con la toxicidad del aldehido. | |
| MX2018002155A (es) | Compuestos deuterados y usos de los mismos. | |
| CO2019001625A2 (es) | Compuestos de captura de aldehído y usos de los mismos | |
| ZA202502750B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| ZA201903091B (en) | Methods of treating inflammatory conditions | |
| MX2023014509A (es) | Compuestos atrapadores de aldehidos heterociclicos y usos de los mismos. | |
| EA202090871A1 (ru) | Ингибирование убиквитин-специфической пептидазы 30 | |
| EA201691514A1 (ru) | Соединения | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| WO2016100162A3 (en) | 5,5-bicyclic oxazole orexin receptor antagonists | |
| EA201991387A1 (ru) | ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ | |
| EA201792604A1 (ru) | Ингибиторы аутотаксина и их применения | |
| EA202090414A1 (ru) | Соединения и их применение | |
| EA201792610A1 (ru) | Способ лечения неврологического заболевания | |
| MA38493B1 (fr) | Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| PH12017500114A1 (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
| EA202191115A1 (ru) | Новые пиридазины | |
| EA202091524A1 (ru) | Ингибиторы рецептора, активируемого протеазой 2 | |
| WO2017103892A3 (en) | Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease | |
| WO2015189830A9 (en) | Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease | |
| EA201990393A1 (ru) | Композиции и способы для ингибирования masp-3, применяемые в целях лечения различных заболеваний и расстройств | |
| EA201992397A1 (ru) | Соединения для лечения эпилепсии, нейродегенеративных нарушений и других нарушений цнс | |
| MA51297B1 (fr) | Quinazolinones en tant qu'inhibiteurs de parp14 |